Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Contributed by: Business Wire

Logo

Tags

Oncology

Medical Supplies

Health

Clinical Trials

Pharmaceutical

Biotechnology

BAP Pharma

More Like This

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma